Screener
Cytokinetics CYTK Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Cytokinetics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338217
FAQ
- What is Cytokinetics's cash & equivalents?
- Cytokinetics (CYTK) reported cash & equivalents of $255.27M in Q2 2026.
- How has Cytokinetics's cash & equivalents changed year-over-year?
- Cytokinetics's cash & equivalents increased by 240.6% year-over-year, from $74.94M to $255.27M.
- What is the long-term trend for Cytokinetics's cash & equivalents?
- Over 5 years (2020 to 2025), Cytokinetics's cash & equivalents has grown at a 8.1% compound annual growth rate (CAGR), from $82.99M to $122.52M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Cytokinetics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude